The world’s first CRISPR-based therapy offers hope of a functional cure for a devastating blood disorder.
What is Sickle Cell Disease?
Sickle Cell Disease (SCD) is a monogenic blood disorder caused by a single point mutation in the HBB gene. This point mutation substitutes valine for glutamic acid at position 6 of the β-globin chain. Resulting in the production of haemoglobin S (HbS).
In conditions with low oxygen, HbS molecules polymerise, distorting red blood cells into rigid, cresent-shaped forms. These sickled cells are:
- Less deformable, impairing microvascular passage.
- Have a shorter lifespan, leading to chronic haemolytic anaemia.
- Prone to aggregation, causing vaso-occlusion, tissue ischemia, and recurrent pain crises.
The consequences of this include: reduced oxygen delivery, end-organ damage (kidney, lung, brain), functional asplenia, and shortened life expectancy.
Current treatments (hydroxyurea, blood transfusions, bone marrow transplantation) only partially address these pathophysiological processes.
How CRISPR Works in Sickle Cell Disease?
CRISPR-Cas9 is a genome-editing tool that acts as molecular scissors, making precise cuts in DNA. In SCD treatment (Casgevy), the goal is not to repair the HbS mutation directly, but instead to reactivate fetal haemoglobin (HbF) production.
The mechanism of action:
- In early life, HbF prevents sickling, its expression is typically silenced in adulthood by transcription factor BCL11A.
- Using CRISPR-Cas9, hematopoetic stem cells are edited ex vivo to disrupt the BCL11A enhancer region.
- Once reinfused into the patient (following conditioning chemotherapy), these edited cells continuously produce HbF.
- HbF inhibits HbS polymerisation, maintaining red blood cell flexibility, and improving oxygen delivery, even in hypoxic environments.
This technique directly addresses the disease’s molecular pathology, offering more than symptomatic relief.
Evidence from Clinical Trials
Although the theoretical techniques sound promising, CRISPR based therapy must prove both safety and efficacy in clinical trials. A crucial set of clinical trials that investigated this is the Exa-cel trials (NEJM, 2023).
These trials demonstrated remarkable outcomes:
- More than 90% of treated patients remained free of vast-occlusive crises after infusion.
- Sustained increases in HbF levels (above 40%) and improved total haemoglobin.
- Durable engraftment of edited stem cells with no reported off-target genomic edits.
The side effects demonstrated were primarily related to the conditioning regimen (myeloablation with chemotherapy), not the CRISPR editing itself.
Considerations in Regard to CRISPR Based Therapy for the Treatment of Sickle Cell Disease
The approval of CRISPR-based therapy for sickle cell disease is a historic milestone, as it is the first gene-editing treatment approved for human disease by the FDA (2023). Unlike existing treatments, it offers the possibility of a functional cure rather than symptomatic management, transforming the therapeutic methodologies for patients with SCD. Additionally, the success of this approach serves as a proof-of-concept for applying similar strategies to other monogenic diseases such as β-thalassemia and muscular dystrophy.
Although this is promising, significant challenges remain. CRISPR based therapy requires advanced facilities and stem cell transplantation expertise, limiting accessibility. Its cost, which currently exceeds $2 million per patients, raises major equity concerns, particularly as SCD disproportionally affects individuals in low-resource areas such as Sub-Saharan Africa. Additionally, the conditioning regimen involves myeloablation, which carries inherent risks, such as infertility, infection, and secondary malignancy. Finally, although initial data suggests there is a benefit, the long-term safety and effectiveness of CRISPR editing must be closely monitored to ensure that unforeseen genetic effects do not arise over time.
Overall, these factors demonstrate both the unprecedented promise of CRISPR therapy and the need to address its current limitations in order for it to be widely adopted a standard of care.
The Future of CRISPR Based Therapy for Sickle Cell Disease
To fully realise the potential of CRISPR based therapies and make them a global solution, future research must focus on overcoming the remaining scientific, clinical, and ethical hurdles.
This includes:
- Developing non-toxic conditioning regimens to replace chemotherapy.
- Reducing costs and expanding access to regions most burdened by SCD.
- Ensuring long-term safety of genome editing.
- Exploring next-generation tools (base editors, prime editing) for even more precise correction.
Conclusion
The approval of CRISPR based therapy for Sickle Cell Disease marks a shift from reactive symptom management to proactive, genetic-level intervention. Whilst barriers remain in cost and access, this breakthrough offers genuine hope of transforming the quality of life for millions of patients, and sets the stage for a future where genetic diseases can be edited at their source.
References
Frangoul, H., et al. (2021). CRISPR–Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. New England Journal of Medicine, 384(3), 252–260.
Esrick, E. B., et al. (2021). Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. New England Journal of Medicine, 384(3), 205–215.
Vertex Pharmaceuticals & CRISPR Therapeutics. (2023). Exa-cel Clinical Trial Results Presented in NEJM.
U.S. Food & Drug Administration (FDA). (2023). FDA Approves First CRISPR-Based Therapy for Sickle Cell Disease.
Musunuru, K., & Orkin, S. H. (2022). Developing Genome Editing for Human Diseases: Progress and Prospects. Nature Medicine, 28, 1473–1483.
Ribeil, J. A., et al. (2017). Gene Therapy in a Patient with Sickle Cell Disease. New England Journal of Medicine, 376, 848–855.
Canver, M. C., & Orkin, S. H. (2023). Genome Editing for Hemoglobinopathies: Clinical Advances and Challenges. Science, 379(6636), 37–42.